The scope of a marketing agreement that allows Siemens Medical Solutions to market Gamma Medica's molecular imaging animal scanner has been expanded to cover worldwide markets. The two companies began their alliance last July when Siemens obtained U.S. marketing rights for the scanner. The expanded agreement covers X-SPECT, Gamma Medica's second-generation MicroSPECT system. This dual-modality system for preclinical imaging combines SPECT with CT. Designed for in vivo imaging of small animals, it is used primarily in the study of disease processes and for drug development.
